Stifel Nicolaus Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $254.00

Key Points

• Stifel Nicolaus has raised the price target for Ascendis Pharma A/S (NASDAQ:ASND) from $212.00 to $254.00, indicating a potential upside of 41.78% from the stock's previous close.
• Other analysts, including JPMorgan and Citigroup, have also increased their price targets, with an average target of $226.80 and a consensus rating of "Moderate Buy."
• Ascendis Pharma reported an earnings per share (EPS) of ($0.93), exceeding analyst expectations and generating revenue of $216.28 million for the quarter.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price objective increased by equities researchers at Stifel Nicolaus from $212.00 to $254.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a "buy" rating on the biotechnology company's stock. Stifel Nicolaus' price target suggests a potential upside of 41.78% from the company's previous close.

ASND has been the subject of several other reports. JPMorgan Chase & Co. boosted their target price on shares of Ascendis Pharma A/S from $245.00 to $254.00 and gave the company an "overweight" rating in a research note on Tuesday, July 29th. Citigroup boosted their price target on shares of Ascendis Pharma A/S from $213.00 to $243.00 and gave the stock a "buy" rating in a report on Friday, July 11th. Wells Fargo & Company reiterated an "overweight" rating on shares of Ascendis Pharma A/S in a research note on Friday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $200.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, May 12th. Finally, Morgan Stanley started coverage on Ascendis Pharma A/S in a research note on Thursday, July 3rd. They issued an "overweight" rating and a $250.00 price objective for the company. One analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $226.80.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND traded down $11.20 on Friday, reaching $179.15. 315,883 shares of the company's stock traded hands, compared to its average volume of 485,150. The stock has a 50 day moving average price of $173.47 and a 200-day moving average price of $158.42. The firm has a market cap of $10.95 billion, a price-to-earnings ratio of -28.53 and a beta of 0.41. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $199.99.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping analysts' consensus estimates of ($1.42) by $0.49. The company had revenue of $216.28 million during the quarter, compared to analysts' expectations of $163.17 million. As a group, equities research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Ascendis Pharma A/S during the fourth quarter worth approximately $28,000. Compagnie Lombard Odier SCmA acquired a new stake in shares of Ascendis Pharma A/S during the second quarter worth about $39,000. First Horizon Advisors Inc. acquired a new position in Ascendis Pharma A/S in the 2nd quarter valued at about $41,000. Brooklyn Investment Group raised its stake in Ascendis Pharma A/S by 332.9% during the 1st quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company's stock valued at $55,000 after acquiring an additional 273 shares during the last quarter. Finally, Hantz Financial Services Inc. lifted its position in Ascendis Pharma A/S by 291.1% during the 2nd quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company's stock worth $61,000 after acquiring an additional 262 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.